BMY-28190, a novel antiviral antibiotic complex.
BMY-28190, an antibiotic complex active against herpes simplex virus type 1 (HSV-1) was produced by the cultured broth of Streptoalloteichus hindustanus sp. nov., a producing strain of tallysomycins A and B. The antibiotic complex was recovered from the broth with Amberlite IRC-50 resin and separated from the coproduced tallysomycins and nebramycins by a series of chromatographies. BMY-28190 exhibited weak inhibitory activity toward Gram-positive and Gram-negative bacteria and strong inhibitory activity toward HSV-1. Structural studies disclosed that BMY-28190 is a novel complex of gamma-poly-D-alpha, gamma-diaminobutyric acids with an average MW of 5,130.
Bristol-Myers Research Institute, Ltd., Tokyo Research Center, Japan.
H
H
Ohkuma
O
O
Tenmyo
M
M
Konishi
T
T
Oki
H
H
Kawaguchi
D000192:Actinomycetales / Q000378:metabolism*; D000613:Aminobutyrates / Q000302:isolation & purification* / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000302:isolation & purification* / Q000494:pharmacology; D000998:Antiviral Agents / Q000302:isolation & purification* / Q000494:pharmacology; D001704:Biopolymers; D055598:Chemical Phenomena; D002621:Chemistry; D011107:Polylysine / Q000494:pharmacology; D011108:Polymers / Q000302:isolation & purification* / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000613:Aminobutyrates; D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D001704:Biopolymers; D011108:Polymers; C057097:gamma-poly-alpha,gamma-diaminobutyric acid; D011107:Polylysine